Lead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus ahead

Thursday's quarterly report from Novo Nordisk will emphasize the pharmaceutical company's diabetes 2 treatments Ozempic and Rybelsus, as well the new weight-loss drug Wegovy, which is in high demand.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Novo Nordisk is looking into a growth-heavy Q2, as it has had tailwind with diabetes 2 drugs Ozempic and Rybelsus, and as the demand is high for its new weight-loss treatment Wegovy.

The results appear extra positive, when compared with the second quarter of last year. In the first quarter of 2020, as the covid-19 crisis was starting, patients began to stockpile medicine, after which growth receded for a while.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs